Asceneuron
Targeting Tau
- Headquarters
- Eysins
- Employees
- 11–50
- Business Model
- B2B
- Website
- asceneuron.com
About
Asceneuron is a clinical-stage biopharmaceutical company focused on discovering and developing orally bioavailable small molecule therapeutics for neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, and orphan tauopathies. The company's lead program, ASN51, targets tau pathology — a hallmark of multiple neurodegeneration diseases — and advanced into Phase 2 clinical trials following a $100 million Series C financing in 2024. Asceneuron is headquartered in Eysins, Switzerland and is backed by EQT Life Sciences and Sofinnova Partners.
Summary
Asceneuron is a Biotech company based in Eysins, Switzerland.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...